anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a compound preparation, which is used to treat beriberi infected by mycotic, tinea corporis, tinea cruris and so on. The compound preparation is an achievement of constant trials and summarization of the inventor during a plurality of years of treatment practice. The main compositions of the product are high-concentration vinegar and western medicine ABC tablets. The high-concentration vinegar has the effects of powerful sterilization and disinfection, the ABC tablets have the effects of reducing fever, analgesia and antiphlogosis, and the combined use of the two compositions can effectively and quickly treat various mycotic infection diseases. The product is mainly characterized in that: the product has unique prescription composition, quick treatment, exact healing effect, uneasy recurrence, short treatment course, low treatment cost, and no side effects. Practice proves that the effective rate of the compound preparation on the treatment of the beriberi can reach 100 percent, and the recurrence rate is not higher than 10 percent.
A method of diagnosing cancers associated with the absence of the gene encoding human p58 protein, such as neuroblastomas, ductal carcinomas of the breast, malignant melanoma, Merkel cell carcinoma or endocrine neoplasia is set forth. In one embodiment, cells, especially in metaphase, are prepared from a tissue to be examined. There is then performed an in situ hybridization with a labelled probe including a DNA sequence which is either complementary to the p58 protein kinase gene or to a portion of the p58 kinase gene which is long enough to identify such gene, if present.  Determination of the presence of the absence of the gene on the number 1 chromosome indicates that a cell is cancerous or, at the very least, potentially cancerous. In a second embodiment, antibodies specific to p58 protein kinase are employed for its detection. Kits including a probe or antibody as discussed above are also set forth.
With the development of robotic surgery systems, their unique advantages over traditional laparoscopic surgery systems, such as a three-dimensional 10-fold magnified view, seven degrees of freedom for flexible wrist movements, tremor filtering, and good ergonomic design, have significantly improved the precision and quality of surgery. The literature has reported that, compared with the laparoscopic surgery system, the robotic surgery system can reduce intraoperative blood loss and the conversion rate to laparotomy, in addition to the dissection of more lymph nodes. Therefore, robotic surgery has become increasingly popular. As the economy develops and surgeons gain more experience in LPD, many are shifting their focus to robotic pancreatoduodenectomy after mastering laparoscopic techniques. There are a few reports on the RPD learning curve for surgeons with extensive experience in LPD. Therefore, this study aimed to investigate the number of cases required for such surgeons to overcome the learning curve for RPD and to analyze the impact of different phases of the learning curve on perioperative outcomes.
OBJECTIVES: To explore the trajectories and the change-points of global and five domain-specific cognitive functions before the onset of Alzheimer's disease (AD).
METHODS: Data was retrieved from the Alzheimer's Disease Neuroimaging Initiative with follow-up from 2005 to 2022. Participants with mild cognitive impairment (MCI) at baseline and those who progressed to AD during follow-up were included. The time of AD onset was defined as the visit time when participant was first diagnosed as AD during follow-up. Global and five domain-specific cognitive functions (immediate memory, visuospatial ability, language, processing speed and executive function) were assessed by Mini-Mental State Examination, Immediate recalling trials of Rey Auditory Verbal Learning Test, Clock Drawing Test, Animal Fluency Test, Part A and B of Trail Making Test, respectively. Their trajectories and change-points before AD onset were explored by generalized additive mixed models and piecewise linear regression models, respectively.
RESULTS: 349 participants were diagnosed as MCI at baseline and converted to AD during follow-up, who were included in this study. They had been visited on an average of 4.6 times (SD = 2.1, range = 2.0-13.0), with a total of 1593 visits. Their mean baseline age and AD onset age were 74.4 (SD = 6.4, range = 60.0-88.4) and 77.0 (SD = 6.8, range = 60.5-94.7) years, respectively. Baseline age and educational year were significantly associated with global cognitive, immediate memory, language and executive function. Men presented better global cognitive function (β = 0.54, p < 0.05) but poorer immediate memory (β = -1.72, p < 0.05) than women. Immediate memory and visuospatial ability showed the earliest change-points at 4 years before the onset of AD (Note as T-4years), followed by language (T-3.5years), executive function (T-2.5 years), processing speed (T-2.0 years), and finally the global cognitive function (T-1.5years).
CONCLUSIONS: The trajectories of the six neuropsychological scores were non-linear and showed deterioration in functions over time. Immediate memory and visuospatial ability showed the earliest change-points prior to AD onset.
People with dyslexia, a neurodevelopmental disorder of reading, are highly attuned to the emotional world. Compared with their typically developing peers, children with dyslexia exhibit greater autonomic nervous system reactivity and facial behaviour to emotion- and empathy-inducing film clips. Affective symptoms, such as anxiety, are also more common in children with dyslexia than in those without. Here, we investigated whether the startle response, an automatic reaction that lies at the interface of emotion and reflex, is elevated in dyslexia. We measured facial behaviour, electrodermal reactivity (a sympathetic nervous system measure) and emotional experience in response to a 100 ms, 105 dB unanticipated acoustic startle task in 30 children with dyslexia and 20 comparison children without dyslexia (aged 7-13) who were matched on age, sex and nonverbal reasoning. Our results indicated that the children with dyslexia had greater total facial behaviour and electrodermal reactivity to the acoustic startle task than the children without dyslexia. Across the sample, greater electrodermal reactivity during the startle predicted greater parent-reported anxiety symptoms. These findings contribute to an emerging picture of heightened emotional reactivity in dyslexia and suggest accentuated sympathetic nervous system reactivity may contribute to the elevated anxiety that is often seen in this population.
Medicinal and pharmaceutical preparations, disinfectants, and cosmetics, in the form of solutions or suspensions of solids in liquids, or emulsions of liquids, are solidified by addition of caustic alkalis or ammonia and small amounts (of the order of 0.5 to 2 per cent of the total weight) of resin acids.  The products are stored in collapsable tubes provided with filters.  All preparations which do not react with resin acids or their salts or the alkali can be treated, for example solutions of solids in hydrocarbons or emulsions of hydrocarbons with water or aqueous solutions, oils, or glycerine.  The following substances are suitable: aliphatic hydrocarbons, benzene and its homologues, alicyclic compounds, ethers, esters, organic salts, mixed fats, aromatic ketones, terpenes, camphor, compounds containing condensed aromatic nuclei, and substitution products of these. Reactive substances such as acids, alcohols, amines, aliphatic ketones, aldehydes, heterocyclic compounds, and quinones can only be treated when present to at most about 5 to 10 per cent in the aforementioned substances.  Solutions, emulsions, or suspensions of solids in aliphatic hydrocarbons admixed with about 2 to 10 per cent of aromatic hydrocarbons, chloroform, or ether are particularly stable.  Addition of aqueous ammonia is advantageous, gaseous ammonia or hydrocarbon solutions less favourable. According to examples: (1) A solution of camphor and abietic acid in toluene is mixed with heptane containing oil of Neroli and 10 per cent aqueous ammonia added with stirring; (2) chlorothymol and abietic acid are dissolved in ether and toluene, mixed with octane, and aqueous ammonia added; (3) a mixture of menthol and abietic acid in chloroform, and Eutirsol (ammonium sulphoichthyolicum depuratum) in cyclohexane is solidified in the same manner; (4) sulfoform (tri-phenyl-stibine sulphide) and abietic acid in ethyl alcohol and chloroform, together with ethyl salicylate in octane are treated with aqueous ammonia; (5) thymol and abietic acid in chloroform and benzine are mixed with an emulsion containing lime water, paraffin, olive oil and aqueous ammonia.  The Specification as open to inspection under Sect. 91 refers to the solidification of liquid medicinal, pharmaceutical or like substances.  This subject-matter does not appear in the Specification as accepted.
Single center, open-label, baseline-controlled study evaluating the use of a Sciton fractionated ablative laser in the treatment of Hidradenitis Suppurativa (HS) scarring. The device is FDA approved for the treatment of scarring in all skin types. The study team seeks to observe the efficacy and tolerability in patients without active HS lesions. The study may enroll up to 19 subjects looking for improvement in their HS scarring in the axillary region. The subjects will receive treatment with the Sciton Joule Er:YAG 2940nm laser along with treatment with topical tretinoin, hydroquinone, and hydrocortisone starting 1 month prior to first laser treatment as per standard of care for scar treatment. Each patient will receive 3 treatments spaced approximately one month apart. The patients will be surveyed about their quality of life due to HS scarring, as well as their perspectives on their axillary scarring before and after their assigned treatments. All patients included in the study will have no contraindications to either laser or the use of standard treatment protocol (tretinoin and hydroquinone). Subjects in the laser group will complete a DLQI (Dermatology Life Quality Index) survey, patient satisfaction survey, and clinical photographs at each treatment visit and at follow-up 1, 2, and 3 months after the last treatment. Subjects in the topical treatment group will be evaluated at the initial visit, month 3 and month 6.
Zeaxanthin, a dietary carotenoid that occurs in very small quantities in corn, spinach, and other dietary sources, can reduce light hyper-sensitivity and various related conditions (such as migraine or other recurrent headaches) in people who suffer from it. Preferred dosages range from about 10 to about 100 mg per day, depending on the severity of condition, and the weight and medical status of the person. High dosages during an initial “buildup” dosing regimen can promote increased concentrations in the macula and lens, and lower dosages can then be used for maintenance purposes. Lutein may be able to achieve similar results, but because of certain molecular and cellular factors, zeaxanthin is preferable. Additional active agents (such as bilberry or other plant extracts, Vitamins C or E, zinc, etc.) can also be included or coadministered with any such formulations.
BACKGROUND: Sexually transmitted infections (STIs) and STI treatment remain a challenge in public health. There is little understanding of related factors influencing health seeking behaviour and delay of care among clinic attendees in Jamaica.
AIM: To determine socio-demographic profile of clinic attendees with STI and identify factors associated with delay in seeking care for STI-related symptoms.
METHODS: A cross-sectional study was done. 201 adult patients presenting with STI symptoms from four health centres in Kingston and St Andrew were selected. A 24-item interviewer-assisted questionnaire was used to obtain data on socio-demographic characteristics, patients' symptoms and duration, previous STIs, knowledge of complications and seriousness of STIs, and factors influencing decision to seek medical care.
RESULTS: Almost 75% delayed seeking care for STIs. Recurrent STIs was identified in 41% of patients. 'Could not find time' was the most commonly reported reason for delay in seeking care (36%). Females were 3.4 times more likely to delay seeking care for STI symptoms than males (OR 3.42, 95% CI: 1.73-6.73). Those with primary level education and below were 5 times more likely to delay seeking care for STI symptoms than those with at least secondary level education (OR 5.05, 95% CI: 1.09-23.46). Participants viewed staff as confidential (68%) and 65% thought health-care workers spent adequate time during consultations.
CONCLUSION: Lower education level and the female gender are associated with delay in seeking care for STI-related symptoms. These factors should be considered when developing interventions to reduce delay in care for STI-related symptoms.
A process for modifying the physico-chemical properties of chemical substances used as drugs either by the formation of derivs. or by the addn. of substances with the desired properties which interact at the surface of the principal substance. The process for desired modification of properties takes place at the surface of the substance to be treated in the form of a solid soln. or a solid semi-soln., or by inclusion into the crystal structure by ionic penetration, or by surface adherance. Included are processes such as neutralisation of basic and acidic cpds. Modification of the physico-chemical properties of drugs to allow easier formulations, adsorption, improved activity etc.
Participants will be asked to complete the tubomanometry (TMM) then EarPopper plus tympanometry tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize Eustachian tube (ET) pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, "Fish" maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening.
Gastroenteritis in children utilizes significant health care resources and has a significant impact on children, caregivers and society. In the United States, gastroenteritis accounts for more than 1.5 million outpatient visits and 200,000 hospitalizations per year. Data from British Columbia indicate that gastroenteritis annually accounts for 12 million missed workdays by adults and 10 million missed school days by children in this province alone. Canadian data, including the cost of work absenteeism, report the mean annual cost/gastroenteritis case to be $1,089.

Although medications have not routinely been recommended, acute gastroenteritis in children can result in significant morbidity. Thus, physicians and caregivers desire treatment options to reduce the burden of disease. Recently, ondansetron, an antiemetic agent has been found to be effective in pediatric gastroenteritis, and is now frequently employed to reduce vomiting. Probiotics agents may represent another valuable treatment option. Since the early 1990s, research has been conducted on the effects of probiotics, defined as viable microbial preparations that have a beneficial effect on the health and well being of the host.

A recent Cochrane Database systematic review recently concluded that "probiotics appear to be a useful adjunct to rehydration therapy in treating acute, infectious diarrhea." However, the review also concluded that more research is needed to determine which specific probiotic regimens should be employed in specific patient groups. The later statement is of particular importance in North America as probiotics are not a mainstay of clinical practice. While only 18% of Canadian physicians are aware of research on probiotics, 82% feel that more probiotic research is needed, and 76% feel there is a role for probiotics in their practice. This discrepancy likely is due to the absence of probiotic trials in North American patients and because the outcome measures evaluated often have had limited clinical applicability. Since most episodes of acute diarrhea require no specific treatment, cost-effectiveness analyses are also required before the widespread use of probiotics can be endorsed.
To provide a multilayer cleansing cosmetic that is combined with a glycerol fatty acid ester, a naturally occurring surfactant, to exhibit increased cleansing power and safety and have an appearance appealing to consumers.SOLUTION: As a result of conducting extensive studies, the inventor of the present invention have obtained a multilayer cleansing composition containing the following (a)-(d) as essential components. (a) denotes (poly)glycerol fatty acid esters, classified by HLB under (a1), (a2), and (a3). (a1) is a glycerol fatty acid ester with an HLB of 3 or more and less than 6 and a glycerin polymerization level of 1-10; (a2) is a polyglycerol fatty acid ester with an HLB of 6 or more and less than 12; and (a3) is a polyglycerol fatty acid ester with an HLB of 12 or more and 18 or less. (b) denotes one or more polyols. (c) denotes water. (d) denotes oil.SELECTED DRAWING: None
Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with morphine sulfate extended-release tablets. [see Warnings and Precautions (5.3), Patient Counseling Information (17)] . 

Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription directly from a pharmacist, or as part of a community-based program).

Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, and a history of opioid use disorder, or prior opioid overdose. The presence of risk factors of overdose should not prevent the proper management of pain in any given patient [see Warnings and Precautions (5.1, 5.3, 5.5)] . 

Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.
Participants will receive a single dose of ASP2713. Up to 8 dose levels will be administered in the study.
OBJECTIVES: I. Determine the safety, tolerability, and toxicity of 3-AP in patients with advanced malignancies. II. Determine the maximum tolerated dose and recommended phase II dose of this treatment in these patients. III. Determine the pharmacokinetic parameters of this treatment in these patients. IV. Determine the tumor response in these patients treated with this regimen.

OUTLINE: This is a dose escalation, multicenter study. Patients receive 3-AP IV continuously over 96 hours. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with complete response receive treatment for 1 course past the course in which the complete response was documented; patients with partial response may receive treatment for up to 1 year; and patients with stable disease may receive treatment for up to 6 months. During the accelerated phase of the study, cohorts of 1 patient each receive escalating doses of 3-AP until one patient experiences dose limiting toxicity (DLT) or 2 different patients experience grade 2 toxicity during any course. When the accelerated phase ends, cohorts of 3-6 patients receive escalating doses of 3-AP until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT.

PROJECTED ACCRUAL: Approximately 21 patients will be accrued for this study.
This surveillance study is a two-arm prospective evaluation of parasitological responses to directly observed treatment with CQ (vs. placebo) for the clearing of asymptomatic parasitemia. People with asymptomatic P. falciparum parasitaemia, defined as the presence of a P. falciparum infection in the absence of any clinical symptomatology including fever, history of fever in the preceding 24 hours, malaise, fatigue, chills, or any other symptoms that may be derived from the malarial infection, who meet the study inclusion criteria will be enrolled, treated on site with CQ phosphate (25mg/Kg CQ base divided in three daily doses: 10mg/kg day 1 (usually 4 tablets); 10mg/kg day 2 (4 tablets) and 5mg/kg day 3 (2 tablets)) or placebo pills (same schedule, 4 tablets day one and two; and 2 tablets on day three), and monitored for 28 days. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and laboratory examinations. On the basis of the results of these assessments, the patients will be classified as having therapeutic failure (early or late) or an adequate response. The proportion of patients experiencing therapeutic failure during the follow-up period will be used to estimate the efficacy of the study drug. PCR analysis will be used to distinguish between a true recrudescence due to treatment failure and episodes of reinfection.
Menopause, which is a natural part of women's life; It is a condition that occurs between the ages of 45-52 on average and is characterized by hormonal changes and cessation of the menstrual cycle. Many symptoms are observed during menopause, such as hot flashes, sleep problems, mood disorders, sexual dysfunction, weight gain, and decline in cognitive functioning. Restless legs syndrome is another symptom that can be seen in all periods of a woman's life, but its frequency and severity increases with menopause. Restless legs syndrome is a neurological problem that occurs usually at night with an irresistible urge to move the legs. There are studies reporting that sleep problems, which are a common problem during the menopausal period, worsen with the addition of restless legs syndrome. Restless legs syndrome and sleep problems are two important factors that negatively affect the quality of life of women in the menopausal period. Alternative and complementary therapies are frequently used among the methods used to cope with menopausal symptoms and symptoms triggered by menopause. These methods include hypnosis, body-mind techniques, cognitive behavioral therapies, aromatherapies, and herbal supplements. It is stated that these techniques reduce the stress of women in the menopausal period and are effective in improving their quality of life. One of these methods is progressive muscle relaxation exercise. Progressive muscle relaxation exercise is a systematic practice that aims to provide deep relaxation by exercising large muscle groups in the body along with breathing techniques. There are studies reporting that PCGE is used effectively in coping with menopausal symptoms. This study aims to evaluate the effect of progressive muscle relaxation exercise on the severity of restless legs syndrome, quality of life and sleep quality related to restless legs syndrome in menopausal women with restless legs syndrome.